CXCR2 and neoplasm: Cheng et al. demonstrated that SB225002, a CXCR2 inhibitor, not only suppressed NSCLC tumor cell EMT in vitro and tumor growth in vivo but also decreased N2-TAN infiltration in the TME [80].